Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of RhuDex granules in primary biliary cholangitis
NL-OMON55327Phase 2Completed
- Sponsor
- AML Clinical Services
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RhuDex in primary biliary cholangitis (PBC) (4 arms), sponsored by AML Clinical Services. Primary endpoint: Relative change in alkaline phosphatase from baseline to end of treatment. Started Jun 2021; status: completed.
02
Drugs
RhuDex
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NL-OMON55327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55327.